Physician profile
Anthony C Carter
NPI 1104890276
$4,399.73
in general payments reported to CMS, 2019-2025
39 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $528 · 2021: $860 · 2022: $648 · 2023: $913 · 2024: $818 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,162 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,161.83 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $842.96 | 2021-2025 | Vraylar, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $425.66 | 2019-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $358.43 | 2021-2025 | Breztri, Airsupra, Evusheld |
| Novo Nordisk INC | $252.28 | 2020-2024 | Wegovy |
| Lilly USA, LLC | $243.07 | 2019-2023 | Mounjaro |
| Amgen INC. | $238.00 | 2020-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $235.94 | 2020-2025 | |
| Glaxosmithkline, LLC. | $185.79 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Sanofi-Aventis U.S. LLC | $168.18 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.58 | 2024-2025 | Caplyta |
| Avanir Pharmaceuticals, INC. | $117.77 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.64 | 2020-2024 | Trintellix |
| Insulet Corporation | $100.27 | 2021-2023 | Omnipod |
| Novartis Pharmaceuticals Corporation | $90.19 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $73.44 | 2024 | Givlaari |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $72.63 | 2022-2023 | Nuedexta, Rexulti |
| Xeris Pharmaceuticals, INC. | $71.57 | 2021-2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $70.18 | 2019-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $69.78 | 2019-2023 | Xarelto |
| Indivior INC. | $68.53 | 2024-2025 | Sublocade |
| Astellas Pharma US INC | $67.20 | 2020-2025 | Veozah |
| Shield Therapeutics INC | $60.41 | 2022-2024 | Accrufer |
| Allergan, INC. | $49.02 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $42.83 | 2020-2023 | Linzess |
| Phathom Pharmaceuticals, INC. | $29.40 | 2024-2025 | Voquezna |
| Scynexis, INC. | $26.26 | 2022 | |
| Corcept Therapeutics | $23.99 | 2025 | Korlym |
| Vanda Pharmaceuticals INC. | $20.99 | 2025 | Hetlioz, Fanapt |
| Circassia INC. | $18.71 | 2019 | |
| Kyowa Kirin, INC. | $18.45 | 2023 | Nourianz |
| Axsome Therapeutics, INC. | $17.70 | 2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $16.73 | 2023 | Quviviq |
| Bausch Health US, LLC | $15.32 | 2020 | |
| Lundbeck LLC | $15.26 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.44 | 2022 | |
| Strongbridge US INC. | $14.42 | 2020 | |
| Eisai INC. | $14.21 | 2021 | |
| Bardy Diagnostics, INC. | $11.87 | 2020 | |
| Dexcom, INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.